Aronson WJ - Search Results

1

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. Whitney CA, et al. Among authors: aronson wj. Prostate Cancer Prostatic Dis. 2019 May;22(2):252-260. doi: 10.1038/s41391-018-0095-0. Epub 2018 Oct 2. Prostate Cancer Prostatic Dis. 2019. PMID: 30279582

2

Can we lower the mortality rate of black men with prostate cancer?

Aronson WJ, Freedland SJ. Aronson WJ, et al. J Urol. 2000 Jan;163(1):150-1. J Urol. 2000. PMID: 10604334 No abstract available.

3

Clinical characteristics in black and white men with prostate cancer in an equal access medical center.

Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6. Urology. 2000. PMID: 10699616

4

Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Jul;56(1):87-91. doi: 10.1016/s0090-4295(00)00587-2. Urology. 2000. PMID: 10869631

5

Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Nov 1;56(5):807-11. doi: 10.1016/s0090-4295(00)00754-8. Urology. 2000. PMID: 11068307

6

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2001 Mar;57(3):476-80. doi: 10.1016/s0090-4295(00)01016-5. Urology. 2001. PMID: 11248623

7

Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer.

Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Aronson WJ, et al. Urology. 2001 Aug;58(2):283-8. doi: 10.1016/s0090-4295(01)01116-5. Urology. 2001. PMID: 11489728 Clinical Trial.

8

Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1016/S0022-5347(01)69076-1. J Urol. 2002. PMID: 11792909

9

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502

10

Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2002 Jul;60(1):84-8. doi: 10.1016/s0090-4295(02)01660-6. Urology. 2002. PMID: 12100929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

280 results

Search Page